Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

Medicine Is Not Ready For Rise Of Deadly Fungi

Evolution is all about organisms and species adapting to their environment in order to survive. Historically, fungi haven't been a big problem in terms of human health because the normal human body temperature has, generally, been enough to kill most fungi. Global warming is killing a lot of fungi, but the fungi that remains is developing resistance to the normal human body temperature. Inside the human body they survive and cause all kinds of health problems.

While fungal diseases have devastated many animal and plant species, humans and other mammals have mostly been spared. That’s probably because mammals have body temperatures too warm for most fungi to replicate as well as powerful immune systems. But climate change may be challenging those defenses, bringing new fungal threats to human health, a microbiologist warns...
Past work has shown a fungus can be coaxed to grow at warmer temperatures in a laboratory setting. “There are millions of fungal species out there,” Casadevall says. “As they adapt to a warmer climate, some of them will then have the capacity to breach our thermal defenses.

https://www.sciencenews.org/article/climate-change-could-raise-risk-deadly-fungal-infections-humans

Brilacidin (IPIX), potentially, could be a major player in combatting the rise of fungal infections caused by climate change.

Extensive in vitro testing of Brilacidin by these research groups against multiple pathogenic human fungi has been completed. Across all pre-clinical studies conducted to date, Brilacidin has now exhibited varying degrees of inhibition against 13 of 19 “priority” fungal pathogens identified by the World Health Organization in need of novel treatments...
...Brilacidin showed potent stand-alone inhibition in multiple isolates of C. neoformans, for which few effective treatments exist...
Brilacidin showed promising stand-alone inhibition as well in multiple isolates of Mucorales, Fusarium sp., C. glabrata, C. parapsilosis, C. guillermondii, Lomentospora prolificans, Scedosporium apiospermum, Blastomyces dermatitidis and Histoplasma capsulatum.
USP researchers have also shown Brilacidin to be synergistic with caspofungin in different types of fungi. Additive effects were similarly observed in Brilacidin combinations with voriconazole and geldanamycin against A. fumigatus, as well as with posaconazole against Mucorales. Separate in vitro laboratory testing evaluating Brilacidin in combination with other conventional antifungals – including caspofungin, fluconazole, posaconazole, amphotericin B and micafungin – demonstrated additive or synergistic inhibition of fungal growth.
Beyond Brilacidin’s broad-spectrum ability to directly inhibit fungal pathogens, Brilacidin may favorably modulate the host response to fungal infections.

http://www.ipharminc.com/press-release/2023/3/15/innovation-pharmaceuticals-announces-new-antifungal-testing-of-brilacidin-by-nihniaid-affiliated-and-other-academic-researchers

The rise in deadly fungi caused by climate change, as well as the lack of effective drugs with which to combat this phenomena, is clearly a trend that's positive for IPIX. This also explains the worldwide interest in Brilacidin as an antifungal.

This is just another reason IPIX is a long-term hold. "The trend is your friend."